Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Antidepressant Effect of Pramipexole in Mice Forced Swimming Test: A Cross Talk Between Dopamine Receptor and Nmda/Nitric Oxide/Cgmp Pathway Publisher Pubmed



Ostadhadi S1, 2 ; Imran Khan M2, 4 ; Norouzijavidan A1 ; Dehpour AR1, 2, 3
Authors
Show Affiliations
Authors Affiliations
  1. 1. Brain and Spinal Cord Injury Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Experimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, International Campus, Tehran, Iran

Source: Biomedicine and Pharmacotherapy Published:2016


Abstract

Pramipexole is a dopamine D2 receptor agonist indicated for treating Parkinson disorder. This study was aimed to investigate the effect of pramipexole in forced swimming test (FST) in mice and the possible involvement of activation of D2 receptors and inhibition of N-methyl-. d-aspartate (NMDA) receptors and nitric oxide-cyclic guanosine monophosphate (NO-cGMP) on this effect. Intraperitoneal administration of pramipexole (1-3 mg/kg) reduced the immobility time in the FST similar to fluoxetine (20 mg/kg, i.p.). This effect of pramipexole (1 mg/kg, i.p.) was ceased when mice were pretreated with haloperidol (0.15 mg/kg, i.p,) and sulpiride (5 mg/kg, i.p) as D2 receptor antagonists, NMDA (75 mg/kg,i.p.), l-arginine (750 mg/kg, i.p., a substrate for nitric oxide synthase) or sildenafil (5 mg/kg, i.p., a phosphodiesterase 5 inhibitor). The administration of MK-801 (0.05 mg/kg, i.p., a NMDA receptor antagonist) l-NG-Nitro arginine methyl ester (. l-NAME, 10 mg/kg, i.p., a non-specific nitric oxide synthase (NOS) inhibitor), 7-nitroindazole (30 mg/kg, i.p., a neuronal NOS inhibitor) and methylene blue (10 mg/kg, i.p.), an inhibitor of both NOS and soluble guanylyl cyclase (sGC) in combination with the sub-effective dose of pramipexole (0.3 mg/kg, i.p.) reduced the immobility. Altogether, our data suggest that the antidepressant-like effect of pramipexole is dependent on the activation of D2 receptor and inhibition of either NMDA receptors and/or NO-cGMP synthesis. These results contribute to the understanding of the mechanisms underlying the antidepressant-like effect of pramipexole and reinforce the role of D2 receptors, NMDA receptors and l-arginine-NO-GMP pathway in the antidepressant mechanism of this agent. © 2016 Published by Elsevier Masson SAS.
Experts (# of related papers)
Other Related Docs
24. Behavioral Despair Associated With a Mouse Model of Crohn's Disease: Role of Nitric Oxide Pathway, Progress in Neuro-Psychopharmacology and Biological Psychiatry (2016)
49. Development of Resistance to Serotonin-Induced Itch in Bile Duct Ligated Mice, Clinical and Experimental Pharmacology and Physiology (2017)